Clinical Trial Update: A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating AK104 in patients with unresectable locally advanced non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 3 | Status: RECRUITING